- The primary endpoint was defined as a patient achieving a ≥20% reduction in weekly PS volume from baseline (immediately before randomization) to Weeks 20 and 246
- Efficacy analysis was performed by comparing the intent-to-treat population in the treatment group and placebo group, respectively1,6
- PS volume adjustments (up to a 30% decrease) and clinical assessments were made at Weeks 2, 4, 8, 12, 20, and 241
How GATTEX works
The half-life of native GLP-2 is ~7 minutes; in adult patients with SBS, the half-life of GATTEX is 1.3 hours.1,2
The amino acid sequence of native GLP-2 and GATTEX are nearly identical, except for a single amino acid substitution—alanine replaced with glycine. This substitution results in decreased degradation by dipeptidyl 22% peptidase-IV (DPP-IV) and an extended half-life.1,3-5
GATTEX enhanced intestinal absorption in patients with SBS4
IN ADULTS, RESULTS SHOWED THAT GATTEX HAD THE ABILITY TO INCREASE INTESTINAL ABSORPTION1,4*

GATTEX enhanced gastrointestinal fluid (wet weight) absorption by approximately 750-1000 mL/day1
Study Design
In a 3-week, Phase 2, open-label, multicenter, dose-ranging study of adult patients with SBS, GATTEX increased the absorptive capacity of the intestine.1
Seventeen patients with SBS (n=2-3 per dosage group) were given daily doses of GATTEX 0.03, 0.10, or 0.15 mg/kg (doses ranged from 0.6 to 3 times the recommended dose).1
All subcutaneous (abdomen) dosages studied, except 0.03 mg/kg/day, resulted in enhanced gastrointestinal fluid (wet weight) absorption of approximately 750-1000 mL/day and increased villus height and crypt depth of the intestinal mucosa.1
The recommended dosage of GATTEX for both adult and pediatric patients is 0.05 mg/kg once daily by subcutaneous injection. The recommended dosage in adult and pediatric patients with moderate and severe renal impairment and end-stage renal disease (estimated glomerular filtration rate [eGFR] less than 60 mL/min/1.73 m2) is 0.025 mg/kg once daily.